Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcmg.2024.05.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elevated Lipoprotein(a) Levels and Massive Ruptured Root and Ascending Aortic Aneurysm.
JACC Case Rep
September 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Cardiac Surgery, St Michael's Hospital of Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Department of P
Background: Rupture of a root and ascending aortic aneurysm is a rare, life-threatening condition requiring prompt recognition and surgical intervention. Elevated lipoprotein(a) levels have been implicated in vascular pathology but are less studied in thoracic aneurysms.
Case Summary: A 61-year-old man who presented with severe dyspnea and chest tightness was found to have a 7.
Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes.
Cureus
July 2025
Pharmacology and Therapeutics, Hamdard Institute of Medical Sciences and Research, New Delhi, IND.
Background Type 2 diabetes (T2D) represents one of the most common metabolic disorders globally. Insulin resistance is a fundamental issue associated with the disorder, wherein cells in the adipose tissue, liver, and muscle resist the action of insulin, leading to dysregulation of glucose metabolism. T2D is a known, significant, and independent risk factor for the development and progression of dyslipidemia, a condition characterized by abnormal lipid levels in the blood.
View Article and Find Full Text PDFPelacarsen: Mechanism of action and Lp(a)-lowering effect.
J Clin Lipidol
June 2025
Atherosclerosis and Lipid-apheresis Center, University of Kansas Medical Center, Kansas City, KS, USA (Dr Moriarty). Electronic address:
Background: Lipoprotein(a) (Lp[a]) is an apolipoprotein B100 (apoB)-containing lipoprotein with a single apolipoprotein(a) (apo[a]) covalently bound to apoB via a disulfide bond and oxidized phospholipids linked to apoB and apo(a), which is associated with proinflammatory, prothrombotic, and proatherogenic mechanisms. Elevated Lp(a) (≥125 nmol/L [≥50 mg/dL]) is an independent, causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD), affecting >1.4 billion individuals worldwide.
View Article and Find Full Text PDFLp(a) as a Risk Factor for Peripheral Artery Disease: Context Is Everything.
Arterioscler Thromb Vasc Biol
September 2025
Robarts Research Institute (M.L.K., M.B.B.), Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada.
Elevated plasma concentrations of Lp(a) (lipoprotein(a)) are an independent and causal risk factor for the development of atherosclerotic cardiovascular diseases, including peripheral artery disease (PAD). Although proatherosclerotic, proinflammatory, procalcific, and prothrombotic effects have been attributed to Lp(a), the precise pathogenic mechanisms by which Lp(a) contributes to these disorders are unclear. Moreover, whether Lp(a) contributes in different ways to atherosclerotic cardiovascular diseases in different vascular sites has not been explored.
View Article and Find Full Text PDFEvaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.
Circulation
September 2025
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.R.B., E.E.B., J.L., S.U., A.F., Z.Y., S.K., B.T., S.H., P.N., A.P.P.).
Background: Despite current treatment strategies for atherosclerotic vascular disease focusing on lifestyle modification and lowering cholesterol, a significant residual risk of major atherosclerotic complication remains, prompting investigation into lipoprotein(a) (Lp(a)) as a potential predictive biomarker. The objective of this study was to determine the usefulness of Lp(a) in identifying patients at high risk of incident extracoronary atherosclerotic vascular disease and complications.
Methods: Data from 460 544 participants in the UK Biobank with prospectively measured Lp(a) concentrations were included in this analysis.